Bicycle Therapeutics plc Deferred Foreign Income Tax Expense (Benefit)
Bicycle Therapeutics plc (BCYC) reported Deferred Foreign Income Tax Expense (Benefit) of -$1.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-03-17
- Bicycle Therapeutics plc deferred foreign income tax expense (benefit) for fiscal 2025 was -$1.30M.
- Bicycle Therapeutics plc deferred foreign income tax expense (benefit) for fiscal 2024 was -$3.77M, a 250.10% decline from fiscal 2023.
- Bicycle Therapeutics plc deferred foreign income tax expense (benefit) for fiscal 2023 was $2.51M.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$1.30M 10-K · filed 2026-03-17 |
| 2024-12-31 | -$3.77M 10-K · filed 2026-03-17 |
| 2023-12-31 | $2.51M 10-K · filed 2026-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |